Pharmacological Overview in Geriatrics: Pharmacodynamics, Pharmacokinetics, Laboratory Monitoring
The goal of pharmacological treatment in geriatric psychiatry is to reduce adverse effects and maximize effectiveness, with the fewest number of medications. To achieve this goal, one must recognize the many pharmacokinetic and pharmacodynamic changes of aging that have a significant impact on geriatric psychopharmacology in the inpatient setting. Pharmacological treatment within the inpatient geriatric psychiatry unit or medicine unit, should include reconciliation of medication lists, along with the review/revision/rationalization of medication regimens. Guidelines specific to prescribing for the geriatric inpatient are reviewed in this chapter, including parsimonious prescribing, appropriate laboratory testing, recognizing the impact of medical co-morbidities, and vigilance for drug-drug interactions and adverse effects.
KeywordsPharmacokinetics Absorption Distribution Metabolism Elimination Pharmacodynamics Polypharmacy Drug-drug interaction
- 1.Centers for Disease Control and Prevention. The state of aging and healthy in America. Atlanta, GA: Createspace Independent Publisher; 2013.Google Scholar
- 2.Bartels SJ, Fortuna KL, Naslund JA. Serious mental disorders in older adults: schizophrenia and other late-life psychoses. In: Segal DL, Gualls SH, Smyer MA, editors. Aging and mental Health. 3rd ed. Hoboken: Wiley-Blackwell; 2018. p. 265.Google Scholar
- 4.Bartol TG. MedScape. [Online]; 2015 [cited 2017 Dec 3. Available from: https://www.medscape.com/viewarticle/847187.
- 7.Ronaldson PT, Bauer B, El-Kattan AF, Shen H, Salphati L, Louie SW. Highlights from the American Association of Pharmaceutical Scientists/International Transporter Consortium Joint Workshop on drug transporters in absorption, distribution, metabolism, and excretion: from the bench to the bedside. Clin Pharmacol Ther. 2016;100(5):419–22.PubMedPubMedCentralCrossRefGoogle Scholar
- 9.Oesterhald JR. Transports. In: Wynn GH, Oesterhald JR, Cozza KL, Armstrong SC, editors. Clinical manual of drug interaction: principles for medical practice. Washington, DC: American Psychiatric Publishing; 2009. p. 43–60.Google Scholar
- 14.McIntyre RS, Baghdady NT, Banik S, Swartz SA. The use of psychotropic drugs in patients with impaired renal function. Prim Psychiatry. 2008;15(1):73–88.Google Scholar
- 23.Aging Brain Program of the Indiana University Center for Aging Research. Aging Brain Care. [Online]; 2012 [cited 2017 12 3. Available from: http://www.agingbraincare.org/uploads/products/ACB_scale_-_legal_size.pdf.
- 28.Howard WT, Warnock JK. Risk factors for falls during treatment of late-life depression. J Clin Psychiatry. 1996;156:2017–8.Google Scholar
- 29.Joo JH, Lenze EJ, Mulsant BH, et al. Risk factors for falls during treatment of late-life depression. J Clin Psychiatry. 1996;57:238–40.Google Scholar
- 30.Alexopolous GS. Pharmacotherapy for late-life depression. J Clin Psychiatry. 2011;72(1):e04.Google Scholar
- 34.Hassamal S, Waller S, Reese K, Testa C. Reversible valproic-acid induced parkinsonism and cognitive impairment in an elderly patient with bipolar I disorder. Turk J Psychiatry. 2016;27(3):213–7.Google Scholar